Time of Dropout From the Liver Transplant List in Patients With Hepatocellular Carcinoma: Clinical Behavior According to Tumor Characteristics and Severity of Liver Disease

被引:4
作者
Salvalaggio, P. R. [1 ]
Felga, G. E. [1 ]
Guardia, B. D. [1 ]
Almeida, M. D. [1 ]
Pandullo, F. L. [1 ]
Matielo, C. E. [1 ]
Evangelista, A. [1 ]
Curvelo, L. [1 ]
Rocco, R. A. [1 ]
Alves, J. A. [1 ]
Meirelles, R. F., Jr. [1 ]
Filho, S. P. M. [1 ]
de Rezende, M. B. [1 ]
Pedroso, P. T. [1 ]
Diaz, L. G. [1 ]
Rusi, M. B. [1 ]
Viveiros, M. M. [1 ]
Neves, D. B. [1 ]
机构
[1] Hosp Israelita Albert Einstein, Liver Transplant Unit, Sao Paulo, Brazil
关键词
CHEMOEMBOLIZATION; SURVIVAL; MODEL;
D O I
10.1016/j.transproceed.2016.06.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Prolonged time on the waiting list affects post-transplant survival of patients with hepatocellular carcinoma (HCC). However, it is not yet known which patients will be at higher risk for early dropout from the list. We investigate specific risk factors for early waiting list dropout in patients with HCC. Methods. This was a single-center, intention-to-treat analysis of adults with HCC, within the Milan criteria, from July 2006 through September 2013. Patients were divided into groups according to waiting list time. The main end point was dropout from the list. Results. The dropout rates of the study cohort at 3, 6, and 12-months were 6.4%, 12.4%, and 17.7%, respectively. Patients who dropped out from the list tended to be older, with blood types A and 0, and with higher Child-Pugh and Model for End-Stage Liver Disease (MELD) scores. They also had larger nodules, responded poorly to trans arterial chemo-embolization (TACE), and had a higher alpha-fetoprotein. Those with blood types B and AB appeared to be protected for dropout (odds ratio [OR] = 0.21, P = .02). Patients who responded to TACE were also protected (OR = 0.22, P < .001). When we looked into time to dropout, the only baseline characteristic that stood out was a higher MELD score (13 for those dropping out up to 90 days vs 10 for those dropping out after 180 days, P = .0025). Conclusions. We conclude that patients who drop out early from the list are primarily driven by the severity of liver disease. Patients who had progressive HCC had a high tumor load and poor response to loco-regional therapies, dropping out from the list after 180 days of inclusion.
引用
收藏
页码:2319 / 2322
页数:4
相关论文
共 12 条
[1]   Short waitlist time does not adversely impact outcome following liver transplantation for hepatocellular carcinoma [J].
Chao, S. D. ;
Roberts, J. P. ;
Farr, M. ;
Yao, F. Y. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (06) :1594-1600
[2]   CURRENT CONCEPTS Hepatocellular Carcinoma [J].
El-Serag, Hashem B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (12) :1118-1127
[3]   Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma [J].
Goldberg, David ;
French, Benjamin ;
Abt, Peter ;
Feng, Sandy ;
Cameron, Andrew M. .
LIVER TRANSPLANTATION, 2012, 18 (04) :434-443
[4]   Alpha-Fetoprotein and Modified Response Evaluation Criteria in Solid Tumors Progression After Locoregional Therapy as Predictors of Hepatocellular Cancer Recurrence and Death After Transplantation [J].
Lai, Quirino ;
Avolio, Alfonso W. ;
Graziadei, Ivo ;
Otto, Gerd ;
Rossi, Massimo ;
Tisone, Giuseppe ;
Goffette, Pierre ;
Vogel, Wolfgang ;
Pitton, Michael B. ;
Lerut, Jan .
LIVER TRANSPLANTATION, 2013, 19 (10) :1108-1118
[5]   Is the Treatment of Hepatocellular Carcinoma on the Waiting List Necessary? [J].
Majno, Pietro ;
Lencioni, Riccardo ;
Mornex, Francoise ;
Girard, Nicolas ;
Poon, Ronnie T. ;
Cherqui, Daniel .
LIVER TRANSPLANTATION, 2011, 17 :S98-S108
[6]   Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis [J].
Mazzaferro, V ;
Regalia, E ;
Doci, R ;
Andreola, S ;
Pulvirenti, A ;
Bozzetti, F ;
Montalto, F ;
Ammatuna, M ;
Morabito, A ;
Gennari, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (11) :693-699
[7]   Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma [J].
Millonig, Gunda ;
Graziadei, Ivo W. ;
Freund, Martin C. ;
Jaschke, Werner ;
Stadlmann, Sylvia ;
Ladurner, Ruth ;
Margreiter, Raimund ;
Vogel, Wolfgang .
LIVER TRANSPLANTATION, 2007, 13 (02) :272-279
[8]   Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma [J].
Otto, Gerd ;
Herber, Sascha ;
Heise, Michael ;
Lohse, Ansgar W. ;
Moench, Christian ;
Bittinger, Fernando ;
Hoppe-Lotichius, Maria ;
Schuchmann, Marcus ;
Victor, Anja ;
Pitton, Michael .
LIVER TRANSPLANTATION, 2006, 12 (08) :1260-1267
[9]   List and Liver Transplant Survival According to Waiting Time in Patients With Hepatocellular Carcinoma [J].
Salvalaggio, P. R. ;
Felga, G. ;
Axelrod, D. A. ;
Della Guardia, B. ;
Almeida, M. D. ;
Rezende, M. B. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 (03) :668-677
[10]   Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation [J].
Sharma, P. ;
Harper, A. M. ;
Hernandez, J. L. ;
Heffron, T. ;
Mulligan, D. C. ;
Wiesner, R. H. ;
Balan, V. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (08) :1957-1962